Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR versus TRIFLURIDINE.
GANCICLOVIR vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category D/X
Category C
Antiviral
Antiviral